切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™可去除血小板的人祖细胞富集试剂盒

通过免疫磁珠负选结合血小板去除技术分离未标记的人祖细胞
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #19356_C

通过免疫磁珠负选结合血小板去除技术分离未标记的人祖细胞

产品优势

  • 快捷、操作简单 ，且无需分离柱
  • 纯度高达75%
  • 分选得到的细胞无标记

产品组分包括

  • EasySep™可去除血小板的人祖细胞富集试剂盒 （产品号 #19356）
    • EasySep™可去除血小板的人祖细胞富集抗体混合物，1 mL
    • EasySep™  Magnetic Particles磁珠 ，2 x 1 mL
  • RoboSep™可去除血小板的人祖细胞富集试剂盒（产品号 #19356RF）
    • EasySep™可去除血小板的 人祖细胞富集抗体混合物，1 mL
    • EasySep™  Magnetic Particles磁珠 ，2 x 1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™ 过滤吸头（产品号 #20125）
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. EasySep™ Magnet
    EasySep™ Magnet

    Magnet for column-free immunomagnetic separation

  2. RoboSep™ Buffer 2
    RoboSep™ Buffer 2

    Cell separation buffer

总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

使用EasySep™可去除血小板的人祖细胞富集试剂盒 ，通过免疫磁珠负选 ，可轻松高效地从新鲜或冻存的人脐带血或其它含大量血小板的细胞样本中分离高纯度造血祖细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。

在此EasySep™负选过程中，表达以下标记物的非目的细胞通过抗体复合物与磁珠标记被靶向去除：CD2、CD3、CD11b、CD11c、CD14、CD16、CD19、CD24、CD56、CD61、CD66b及glyA。通过EasySep™磁极进行无柱分选 ，简单地将目的细胞倾倒或吸取至一个新的试管中即可。 磁珠分选后获得的目的造血祖细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品 ，包括培养基、添加剂、抗体等。

在此EasySep™负选过程中，表达以下标记物的非目的细胞通过抗体复合物与磁珠标记被靶向去除：CD2、CD3、CD11b、CD11c、CD14、CD16、CD19、CD24、CD56、CD61、CD66b及glyA。通过EasySep™磁极进行无柱分选 ，简单地将目的细胞倾倒或吸取至一个新的试管中即可。 磁珠分选后获得的目的造血祖细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品 ，包括培养基、添加剂、抗体等。

在此EasySep™负选过程中，表达以下标记物的非目的细胞通过抗体复合物与磁珠标记被靶向去除：CD2、CD3、CD11b、CD11c、CD14、CD16、CD19、CD24、CD56、CD61、CD66b及glyA。通过EasySep™磁极进行无柱分选 ，简单地将目的细胞倾倒或吸取至一个新的试管中即可。 磁珠分选后获得的目的造血祖细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品 ，包括培养基、添加剂、抗体等。

在此EasySep™负选过程中，表达以下标记物的非目的细胞通过抗体复合物与磁珠标记被靶向去除：CD2、CD3、CD11b、CD11c、CD14、CD16、CD19、CD24、CD56、CD61、CD66b及glyA。通过EasySep™磁极进行无柱分选 ，简单地将目的细胞倾倒或吸取至一个新的试管中即可。 磁珠分选后获得的目的造血祖细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品 ，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
造血干/祖细胞
 
种属
人
 
样本来源
Cord Blood，PBMC
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
免疫，干细胞生物学
 

查看更多 显示更少

实验数据

Starting with Nucleated Cells, the CD34+ Cell Content of the Enriched Fraction Typically Ranges from 50 - 75% Depending on the Quality of the Start Sample

Figure 1. Typical EasySep™ Human Progenitor Cell Enrichment Kit with Platelet Depletion Profile

Starting with nucleated cells, the CD34+ cell content of the enriched fraction typically ranges from 50 - 75%, depending on the quality of the start sample. Note: CD34+ enrichment is dependent on the frequency of CD34+ cells in the start sample, which is variable between cord blood samples. Use of poor quality cord blood or frozen samples may result in lower CD34+ cell content of the enriched fraction.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
EasySep™ Human Progenitor Cell Enrichment Kit with Platelet Depletion
Catalog #
19356
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
RoboSep™ Human Progenitor Enrichment with Platelet Depletion
Catalog #
19356RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Human Progenitor Cell Enrichment Kit with Platelet Depletion
Catalog #
19356
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Human Progenitor Cell Enrichment Kit with Platelet Depletion
Catalog #
19356
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Human Progenitor Enrichment with Platelet Depletion
Catalog #
19356RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Human Progenitor Enrichment with Platelet Depletion
Catalog #
19356RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Human Progenitor Enrichment with Platelet Depletion
Catalog #
19356RF
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (7)

Human CD34+ Cell Isolation Product Selection
Brochure
Human CD34+ Cell Isolation Product Selection
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Hematopoietic Stem and Progenitor Cells - Products for Your Research
Brochure
Hematopoietic Stem and Progenitor Cells - Products for Your Research
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation

常见问题

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

文献 (3)

Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized mice. A. Mart\'inez-Sabadell et al. STAR protocols 2022 dec

Abstract

Immunotherapy has revolutionized cancer treatment, but preclinical models are required to understand immunotherapy resistance mechanisms underlying patient relapse. This protocol describes how to generate an acquired resistance humanized in vivo model to immunotherapies in patient-derived xenografts (PDX). We detail steps to inject human CD34+ cells into NSG mice, followed by generation of immunoresistant PDX in humanized mice. This approach recapitulates the human immune system, allowing investigators to generate preclinical resistance models to different immunotherapies for identifying the resistant phenotype. For complete details on the use and execution of this protocol, please refer to Mart{\'{i}}nez-Sabadell et al., 2022 and Arenas et al. (2021).
View publication
Activation of the receptor tyrosine kinase, RET, improves long-term hematopoietic stem cell outgrowth and potency. W. Grey et al. Blood 2020 jun

Abstract

Expansion of Human Hematopoietic Stem Cells (HSCs) is a rapidly advancing field showing great promise for clinical applications. Recent evidence has implicated the nervous system and glial family ligands (GFLs) as potential drivers of hematopoietic survival and self-renewal in the bone marrow niche, but how to apply this to HSC maintenance and expansion is yet to be explored. We demonstrate a role for the GFL receptor, RET, at the cell surface of HSCs, in mediating sustained cellular growth, resistance to stress and improved cell survival throughout in vitro expansion. HSCs treated with the key RET ligand/co-receptor complex, GDNF/GFRa1, show improved progenitor function at primary transplantation and improved long-term HSC function at secondary transplantation. Finally, we demonstrate that RET drives a multi-faceted intracellular signalling pathway, including key signalling intermediates AKT, ERK1/2, NFkB and p53, responsible for a wide range of cellular and genetic responses which improve cell growth and survival under culture conditions.
View publication
Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. A. Gold et al. Oncogene 2019 jan

Abstract

The cancer stem cell (CSC) model suggests that a subpopulation of cells within the tumor, the CSCs, is responsible for cancer relapse and metastasis formation. CSCs hold unique characteristics, such as self-renewal, differentiation abilities, and resistance to chemotherapy, raising the need for discovering drugs that target CSCs. Previously we have found that the antihypertensive drug spironolactone impairs DNA damage response in cancer cells. Here we show that spironolactone, apart from inhibiting cancerous cell growth, is also highly toxic to CSCs. Notably, we demonstrate that CSCs have high basal levels of DNA double-strand breaks (DSBs). Mechanistically, we reveal that spironolactone does not damage the DNA but impairs DSB repair and induces apoptosis in cancer cells and CSCs while sparing healthy cells. In vivo, spironolactone treatment reduced the size and CSC content of tumors. Overall, we suggest spironolactone as an anticancer reagent, toxic to both cancer cells and, particularly to, CSCs.
View publication
View All Publications

更多信息

更多信息
种属 Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
样本来源 Cord Blood, PBMC
Selection Method Negative
标记抗体
  1. 抗人CD34抗体，克隆8G12
    抗人CD34抗体，克隆8G12

    小鼠单克隆IgG1抗体，抗人CD34

  2. 抗人CD45抗体，克隆2D1
    抗人CD45抗体，克隆2D1

    抗人CD45的小鼠单克隆IgG1抗体

  3. 抗人CD45抗体，克隆HI30
    抗人CD45抗体，克隆HI30

    小鼠单克隆IgG1抗体，抗人、黑猩猩CD45

  4. 抗人CD34抗体，克隆581
    抗人CD34抗体，克隆581

    小鼠单克隆IgG1抗体，抗人CD34

质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.